Patents Examined by Janet L. Andres
  • Patent number: 11904013
    Abstract: An immunogenic composition, a SARS-CoV-2 vaccine and a vector are introduced. The immunogenic composition has a recombinant protein having a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and any polypeptide encoded by a polynucleotide which is at least 80% homologous with SEQ ID NO: 1-4, wherein the recombinant protein contains an IgG1 Fc protein fragment having a length of at least 6 amino acids; or a nucleic acid molecule encoding the recombinant protein. The SARS-CoV-2 vaccine has the above recombinant protein or the nucleic acid molecule encoding the above recombinant protein. The vector has the nucleic acid molecule encoding the above recombinant protein.
    Type: Grant
    Filed: May 3, 2021
    Date of Patent: February 20, 2024
    Assignee: ADIMMUNE CORPORATION
    Inventors: Chih-Hsiang Leng, Po-Hsu Su, Po-Kang Chen
  • Patent number: 11884926
    Abstract: In some aspects, the disclosure relates to compositions and methods for production of recombinant adeno-associated virus (rAAV) particles. The disclosure is based, in part, on isolated nucleic acids and systems that include only two vectors and are suitable for production of multiple different single gene viral vectors in a multiple small-scale campaign mode (e.g., 1013 to 1016 viral particles.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: January 30, 2024
    Assignee: University of Massachusetts
    Inventors: Terence Flotte, Qiushi Tang, Allison Keeler-Klunk, Qin Su
  • Patent number: 11851478
    Abstract: The present disclosure is directed to antibodies binding to and neutralizing Chikungunya virus (CHIKV) and methods for use thereof.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: December 26, 2023
    Assignee: VANDERBILT UNIVERSITY
    Inventor: James E Crowe, Jr.
  • Patent number: 11844818
    Abstract: The present invention relates to a Myoviridae bacteriophage Aer-HYP-3 (Accession number: KCTC 13479BP) isolated from nature, which has the ability to kill Aeromonas hydrophila bacteria and has the genome represented by SEQ ID NO: 1, and to a method of preventing and treating a disease caused by Aeromonas hydrophila bacteria using a composition containing the same as an active ingredient.
    Type: Grant
    Filed: February 18, 2019
    Date of Patent: December 19, 2023
    Assignee: Intron Blotechnology, Inc.
    Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Ji In Jung, Sang Hyeon Kang
  • Patent number: 11826391
    Abstract: An antibacterial formulation having a mixture of bacteriophages with lytic activity against strains of Salmonella spp. and a pharmaceutically and veterinarily acceptable vehicle, pH stabilizer and/or excipients. This formulation is for the prevention and treatment of infectious diseases caused by Salmonella spp. and different serovars; use and method for preventing or treating infectious diseases caused by Salmonella spp. in farm animals by administering the antibacterial formulation to a non-human animal orally.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: November 28, 2023
    Assignee: PHAGELAB CHILE SPA
    Inventors: Nicolas Ferreira Soto, Mauro Canaval Alfaro, Pablo Cifuentes Palma, Daniel Tichy Navarro, Maria Sofia Zamudio Canas, Matias Aguilera Barrios, Trinidad Pizarro Black, Juan Sacre Ravera, Hans Pieringer Castro, Michael Pino Barrientos, Rodrigo Norambuena Venegas, Francisca Contreras Vera, Angelica Zavala Prati
  • Patent number: 11725192
    Abstract: The present disclosure provides methods for the separation and quantification of empty and full viral capsids (e.g., AAV capsids) within a viral preparation, such as a viral pharmaceutical composition or drug product.
    Type: Grant
    Filed: July 12, 2020
    Date of Patent: August 15, 2023
    Assignee: SANGAMO THERAPEUTICS, INC.
    Inventors: Santoshkumar Khatwani, Zhu Pirot
  • Patent number: 11504424
    Abstract: The present invention relates to an attenuated virus strain derived from a human metapneumovirus strain comprising the genome sequence represented by sequence SEQ ID NO. 1, said attenuated strain comprising one or more genetic modifications of said sequence SEQ ID NO. 1 attenuating the virulence of said strain.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: November 22, 2022
    Assignees: UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ECOLE NORMALE SUPERIEURE DE LYON, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE LAVAL
    Inventors: Manuel Rosa-Calatrava, Guy Boivin, Julia Dubois, Mario Andres Pizzorno, Olivier Terrier, Marie-Eve Hamelin, Marie-Helene Cavanagh
  • Patent number: 10729762
    Abstract: This disclosure relates to recombinant bacteria, e.g. L. lactis, expressing heterologous pili containing human immunodeficiency virus (HIV) antigens. In certain embodiments, the recombinant bacteria are administered in combination with other HIV antigens, nucleic acids encoding HIV antigens, recombinant virus encoding HIV antigens, anti-viral agents and/or adjuvants in an effective amount to elicit a mucosal immune response against HIV.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: August 4, 2020
    Assignee: Emory University
    Inventors: Rama Rao Amara, June Scott, Bernard Quigley, Venkateswarlu Chamcha
  • Patent number: 10729754
    Abstract: Methods of treating a patient with human immunodeficiency virus are disclosed. The method includes a providing intradermal and intravenous doses of a aTh1 composition that can increase the CD4+ cells in a patient that are resistant to HIV. The description includes a method for viral load reduction and a viral purge method. The regimen leads to a spike in the viral load and a then a return to baseline or lower levels of the virus and can lead to reduction and/or elimination of the latent viral reservoirs. Kits configured to provide intradermal doses and intravenous doses according to the regimen are also included.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: August 4, 2020
    Assignee: MIRROR BIOLOGICS, INC.
    Inventor: Michael Har-Noy
  • Patent number: 10725056
    Abstract: The present invention relates to metabolic biomarker sets for assessing HIV. In preferred embodiments, the present invention relates to the use of biomarker sets for screening and/or diagnosing HIV infection, for prediction of immunologic response of a mammalian subject to antiretroviral therapy and/or prognosis of HIV disease progression, and for monitoring of HIV disease activity in a mammalian subject. In other embodiments, the invention relates to methods for screening and/or diagnosing HIV infection, for prediction of immunologic response of a mammalian subject to antiretroviral therapy and/or prognosis of HIV disease progression, and for monitoring of HIV disease activity in a mammalian subject, as well as to a kit adapted to carry out the methods. By employing the specific biomarkers and the method according to the present invention it becomes possible to more properly and reliably assess HIV.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: July 28, 2020
    Assignees: BIOCRATES LIFE SCIENCES AG, IDCGS CLINICA DE DIAGNOSTICOS MEDICOS, CENTRO DE GENOMAS
    Inventors: Ismael Dale Cotrim Guerreiro Da Silva, Edson Guimaraes Loturco, Ricoardo Soubie Diaz, Therese Koal
  • Patent number: 10717778
    Abstract: The invention is directed to bispecific molecules comprising an HIV-1 envelope targeting arm and an arm targeting an effector cell, compositions comprising these bispecific molecules and methods of use. In certain aspects, the bispecific molecules of the present invention can bind to two different targets or epitopes on two different cells wherein the first epitope is expressed on a different cell type than the second epitope, such that the bispecific molecules can bring the two cells together. In certain aspects, the bispecific molecules of the present invention can bind to two different cells, wherein the bispecific molecules comprises an arm with the binding specificity of A32, 7B2, CH27, CH28, or CH44.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: July 21, 2020
    Assignees: DUKE UNIVERSITY, MACROGENICS, INC., THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
    Inventors: Barton F. Haynes, Guido Ferrari, Scott Koenig, Leslie S. Johnson, Chia-Ying Kao Lam, Julia A. Sung, David M. Margolis, Liqin Liu, Jeffrey Lee Nordstrom
  • Patent number: 10690668
    Abstract: The invention provides methods of detection and monitoring of polyomavirus reactivation and active polyomavirus infections using a biological fluid sample. Also provided are methods of risk assessment and risk monitoring of developing a polyomavirus-associated disease.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: June 23, 2020
    Assignee: Temple University—Of The Commonwealth System Of Higher Education
    Inventors: Kamel Khalili, Ilker K. Sariyer
  • Patent number: 10676521
    Abstract: The present invention relates to methods and agents for preventing the establishment of HIV-1 latent reservoirs or for reducing the size of the reservoirs. Specifically, the disclosure provides methods and agents for preventing the establishment of HIV-1 latent reservoirs or for reducing the size of the reservoirs, the methods comprising administering to the subject a therapeutically effective amount of an isolated anti-HIV antibody, and administering to the subject two or more viral transcription inducers in effective amounts to induce transcription of an HIV provirus in the cells. Further provided are antibodies and viral transcription inducers used in the methods.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: June 9, 2020
    Assignee: The Rockefeller University
    Inventors: Michel Nussenzweig, Ariel Halper-Stromberg, Ching-Lan Lu
  • Patent number: 10670599
    Abstract: The present invention provides combinations of specific binding proteins, such as immunoglobulins, that are designed to be true combinations, essentially all components of the combination being functional and compatible with each other. The invention further provides a method for producing a composition comprising at least two different proteinaceous molecules comprising paired variable regions, the at least two proteinaceous molecules having different binding specificities, comprising paired variable regions, at least two proteinaceous molecules having different binding specificities, comprising contacting at least three different variable regions under conditions allowing for pairing of variable regions and harvesting essentially all proteinaceous molecules having binding specificities resulting from the pairing.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: June 2, 2020
    Assignee: Merus N.V.
    Inventors: Hendricus Renerus Jacobus Mattheus Hoogenboom, Ton Logtenberg
  • Patent number: 10663468
    Abstract: This invention relates to high throughput methods of determining a viral titer. The instant invention addresses the need for a more rapid and cost effective method of quantitating infectious viral particles in a sample.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: May 26, 2020
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventor: Jean Reyes
  • Patent number: 10590394
    Abstract: A method of non-covalently loading a plant picornavirus is described. The method includes contacting a plant picornavirus in solution with a molar excess of a cargo molecule to load the plant picornavirus with the cargo molecule, and then purifying the loaded plant picornavirus. Examples of cargo molecules include imaging agents, antitumor agents, and antiviral agents. Loaded plant picornaviruses prepared in this manner can be used to delivering cargo molecule to cells.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: March 17, 2020
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Nicole Steinmetz, Daniel Popkin
  • Patent number: 10472412
    Abstract: The invention provides a construct comprising two or more fusion proteins of Formulas (I)-(IV): A-(optional linker)-C-(optional linker)-B (Formula I), B-(optional linker)-D-(optional linker)-E-(optional linker)-B (Formula II), A-(optional linker)-C (Formula III), and B-(optional linker)-D-(optional linker)-E (Formula IV), wherein A denotes an antibody or antibody fragment, B denotes a single domain CD4, C denotes an immunoglobulin light chain constant region D denotes an immunoglobulin heavy chain constant region, and E denotes an Fc region or a portion thereof that is optionally defucosylated.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: November 12, 2019
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Fudan University
    Inventors: Dimiter S. Dimitrov, Weizao Chen, Tianlei Ying
  • Patent number: 10466242
    Abstract: The invention concerns soluble and antigenic HTLV p24 variants that can be fused to chaperones and their use in diagnostic applications such as immunoassays for detecting antibodies against HTLV-I or HTLV-II in an isolated biological sample. In particular, the invention relates to a soluble HTLV-I or HTLV-II p24 antigen comprising either the N- or the C-terminal domain of p24 and lacking the other domain. Moreover, the invention covers recombinant DNA molecules encoding these HTLV-I and -II fusion antigens as well as their recombinant production using expression vectors and host cells transformed with such expression vectors. In addition, the invention focuses on compositions of these HTLV p24 antigens with HTLV gp21 antigen and on an immunoassay method for detection of HTLV antibodies using the antigens of the invention. Also the use of HTLV p24 antigens in an in vitro diagnostic assay as well as a reagent kit for detection of anti-HTLV-antibodies comprising said HTLV antigens is encompassed.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: November 5, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Elke Faatz, Christian Scholz, Peter Muench
  • Patent number: 10426830
    Abstract: The invention provides methods and compositions for eliciting broad immune responses. The methods employ nucleic acid vaccines that encodes highly conserved elements from a virus.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: October 1, 2019
    Assignees: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, UNIVERSITY OF WASHNGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: George Pavlakis, Barbara Felber, James Mullins
  • Patent number: 10426831
    Abstract: The invention provides compositions, methods, and kits for the treatment or prevention of viral infections. The polyvalent (e.g., 2-valent) vaccines described herein incorporate computationally-optimized viral polypeptides that can increase the diversity or breadth and depth of cellular immune response in vaccinated subjects.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: October 1, 2019
    Assignees: Beth Israel Deaconess Medical Center, Inc., TRIAD NATIONAL SECURITY, LLC
    Inventors: Dan H. Barouch, Bette T. Korber, William M. Fischer